巴塞罗那临床肝癌分期与香港肝癌分期对肝细胞癌患者预后预测价值的比较

陈闯; 龙沛雲; 陈洁; 王盼; 黄清云; 臧游亚; 邓国瑜; 林栋毅; 王宗玉

doi:10.3969/j.issn.1001-5256.2019.03.016

巴塞罗那临床肝癌分期与香港肝癌分期对肝细胞癌患者预后预测价值的比较

DOI: 10.3969/j.issn.1001-5256.2019.03.016

1. 广西医科大学附属肿瘤医院
2. 广西医科大学研究生学院
3. 广西省玉林市第一人民医院肿瘤科

基金项目:

广西科技计划项目重大专项(桂科AB18126066)；广西科学研究与技术开发计划项目(桂科攻1598012-54)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1941
- HTML全文浏览量: 28
- PDF下载量: 336
- 被引次数: 0
出版历程
- 收稿日期: 2018-10-17
- 出版日期: 2019-03-20

Value of Barcelona Clinic Liver Cancer staging system versus Hong Kong Liver Cancer staging system in predicting the prognosis of patients with hepatocellular carcinoma

The Affiliated Tumor Hospital of Guangxi Medical University

Research funding:

摘要

摘要: 目的比较临床实践中巴塞罗那临床肝癌（BCLC）分期与香港肝癌（HKLC）分期对肝细胞癌（HCC）患者预后的预测价值。方法回顾性分析2008年7月-2013年7月广西医科大学附属肿瘤医院收治的436例HCC初治病例的临床资料,根据HKLC和BCLC分期系统完成分期评分,采用Kaplan-Meier法绘制生存曲线,并使用log-rank法比较两个分期系统不同分期累积生存率,同时采用Cox模型分别计算两个分期系统的似然比χ2值（LRχ2）,采用受试者工作特征曲线下面积（AUC）和C-index指数分析BCLC分期与HKLC分期系统的辨别力和单一趋势性。结果 HKLC分期中相邻两分期间生存率差异均有统计学意义（P值均<0. 05）。在BCLC分期中除0期与A期外,其余各期中相邻分期间生存率差异亦均有统计学意义（P值均<0. 001）。采用Cox模型分析,HKLC （LRχ2=131. 14）比BCLC分期（LRχ2=100. 69）显示出更好的同质性。BCLC分期与HKLC分期的C-index值分别为0. 703[95%可信区间（95%CI）:0. 675～0. 731]、0. 7...
- 癌,肝细胞 /
- 肿瘤分期 /
- 预后
Abstract: Objective To investigate the value of Barcelona Clinic Liver Cancer ( BCLC) staging system versus Hong Kong Liver Cancer ( HKLC) staging system in predicting the prognosis of patients with hepatocellular carcinoma ( HCC) . Methods A retrospective analysiswas performed for the clinical data of 436 previously untreated patients with HCC who were admitted to The Affiliated Tumor Hospital ofGuangxi Medical University from July 2008 to July 2013, and the staging score was determined according to the HKLC and BCLC staging sys-tems. The Kaplan-Meier method was used to plot survival curves, and the log-rank test was used to compare the cumulative survival ratebetween the patients with different HKLC or BCLC stages. The Cox proportional hazards model was used to calculate the likelihood ratios ( LR χ2) of the two systems. The area under the receiver operating characteristic curve ( AUC) and C-index were used to analyze the dis-criminability and trend of the HKLC and BCLC staging systems. Results There was a significant difference in survival rate between the pa-tients with adjacent HKLC stages ( all P < 0. 05) , and there was also a significant difference in survival rate between all patients with adja-cent BCLC stages ( all P < 0. 001) , except between those with stage 0 and stage A HCC. The Cox proportional hazards model showed that theHKLC system ( LR χ2= 131. 14) had a better homogeneity than the BCLC system ( LR χ2= 100. 69) . The C-index of the BCLC and HKLCsystems was 0. 703 ( 95% confidence interval [CI]: 0. 675-0. 731) and 0. 720 ( 95% CI: 0. 692-0. 748) , respectively, and there was asignificant difference in C-index between the two systems ( P < 0. 001) . There was a significant difference in the AUC of 1-year cumula-tive survival rate between the BCLC system and the HKLC system [0. 783 ( 95% CI: 0. 745-0. 821) vs 0. 811 ( 95% CI: 0. 774-0. 849) , P = 0. 026]. Conclusion Both BCLC and HKLC staging systems have a good value in predicting the prognosis of HCC patients, but the HKLC staging system has a higher value than the BCLC staging system.
- carcinoma, hepatocellular /
- neoplasm staging /
- prognosis

HTML全文

参考文献(21)

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global canc-er statistics 2018:GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries[J]. CACancer J Clin, 2018, 68 (6) :394-424.

[2] SOBIN LH, COMPTON CC. TNM seventh edition:What's new, what's changed:Communication from the International Union A-gainst Cancer and the American Joint Committee on Cancer[J].Cancer, 2010, 116 (22) :5336-5339.

[3] OKUDA K, OHTSUKI T, OBATA H, et al. Natural history ofhepatocellular carcinoma and prognosis in relation to treat-ment. Study of 850 patients[J]. Cancer, 1985, 56 (4) :918-928.

[4] LLOVET JM, BRU C, BRUIX J. Prognosis of hepatocellularcarcinoma:The BCLC staging classification[J]. Semin LiverDis, 1999, 19 (3) :329-338.

[5] KUDO M, CHUNG H, HAJI S, et al. Validation of a new prog-nostic staging system for hepatocellular carcinoma:The JISscore compared with the CLIP score[J]. Hepatology, 2004, 40 (6) :1396-1405.

[6] LLOVET JM, BRUIX J. Prospective validation of the Cancer ofthe Liver Italian Program (CLIP) score:A new prognostic sys-tem for patients with cirrhosis and hepatocellular carcinoma[J]. Hepatology, 2000, 32 (3) :679-680.

[7] Committee of Liver Cancer of Chinese Anti-Cancer A. Clini-cal diagnosis and staging criteria for primary liver cancer[J].J Hepatol, 2001, 9 (6) :324.中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9 (6) :324.

[8] YAU T, TANG VY, YAO TJ, et al. Development of Hong KongLiver Cancer staging system with treatment stratification for pa-tients with hepatocellular carcinoma[J]. Gastroenterology, 2014, 146 (7) :1691-1700. e1693.

[9] GUGLIELMI A, RUZZENENTE A, PACHERA S, et al. Compar-ison of seven staging systems in cirrhotic patients with hepato-cellular carcinoma in a cohort of patients who underwent radio-frequency ablation with complete response[J]. Am J Gastro-enterol, 2008, 103 (3) :597-604.

[10] Ministry of Health of the People’s Republic of China. Diagno-sis, management, and treatment of hepatocellular carcinoma (V2011) [J]. J Clin Hepatol, 2011, 27 (11) :1141-1159.中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[11] BRUIX J, REIG M, SHERMAN M. Evidence-based diagno-sis, staging, and treatment of patients with hepatocellular car-cinoma[J]. Gastroenterology, 2016, 150:835-853.

[12] CHU KK, CHEUNG TT. Update in management of hepatocel-lular carcinoma in Eastern population[J]. World J Hepatol, 2015, 7 (11) :1562-1571.

[13] TORZILLI G, DONADON M, MARCONI M, et al. Hepatecto-my for stage B and stage C hepatocellular carcinoma in theBarcelona Clinic Liver Cancer classification:Results of a pro-spective analysis[J]. Arch Surg, 2008, 143 (11) :1082-1090.

[14] CHEN XP, HUANG ZY. Surgical treatment of hepatocellularcarcinoma in China:Surgical techniques, indications, andoutcomes[J]. Langenbecks Arch Surg, 2005, 390 (3) :259-265.

[15] VITALE A, SARACINO E, BOCCAGNI P, et al. Validation ofthe BCLC prognostic system in surgical hepatocellular cancerpatients[J]. Transplant Proc, 2009, 41 (4) :1260-1263.

[16] YAN X, FU X, CAI C, et al. Validation of models in patientswithhepatocellular carcinoma:Comparison of Hong Kong LiverCancer with Barcelona Clinic Liver Cancer staging system in aChinese cohort[J]. Eur J Gastroenterol Hepatol, 2015, 27 (10) :1180-1186.

[17] YAU T, TANG VY, YAO TJ, et al. Development of Hong KongLiver Cancer Staging System with treatment stratification forpatients with hepatocellular carcinoma[J]. Gastroenterology, 2014, 146 (7) :1691-1700.

[18] LIU PH, HSU CY, LEE YH, et al. Hong Kong Liver CancerStaging System is associated with better performance for hep-atocellular carcinoma:Special emphasis on viral etiology[J].Medicine (Baltimore) , 2015, 94 (41) :e1772.

[19] LEE YS, SEO YS, KIM JH, et al. Can more aggressive treat-ment improve prognosis in patients with hepatocellular carcino-ma? A direct comparison of the Hong Kong liver cancer andBarcelona clinic liver cancer algorithms[J]. Gut liver, 2018, 12 (1) :94-101.

[20] ADHOUTE X, PENARANDA G, BRONOWICKI JP, et al. Use-fulness of the HKLC vs. the BCLC staging system in a Europe-an HCC cohort[J]. J Hepatol, 2015, 62 (2) :492-493.

[21] KOLLY P, REEVES H, SANGRO B, et al. Assessment of theHong Kong Liver Cancer staging system in Europe[J]. LiverInt, 2016, 36 (6) :911-917.

施引文献

资源附件(0)

访问统计